CASE STUDY

During our research phase, an investor asked us to take a look at a company some of his friends had invested in. He wanted some additional data points to help him decide if he too was going to invest.

The company was in the medical space, so we included our healthcare experts in the review.

The company was a unicorn based in Silicon Valley and was very high profile.

It was being exalted as the latest unicorn and its founder, one of the youngest female tech billionaires.

We reviewed materials in the public domain as well as the pitch deck the investor had been given.

Our process highlighted some red flags, including:

  • Claims in the deck that lacked scientific evidence
  • Lack of peer reviews in recognised and reputable medical journals
  • The founder’s inability to answer questions with depth and substance
  • Deflection of questions
  • A board of the who’s who but no-one with relevant medical expertise

We shared our view with the investor.

He decided not to invest.

The company was Theranos, pre-scandal.

The investor is happy.

 

CASE STUDY

During our research phase, an investor asked us to take a look at a company some of his friends had invested in. He wanted some additional data points to help him decide if he too was going to invest.

The company was in the medical space, so we included our healthcare experts in the review.

The company was a unicorn based in Silicon Valley and was very high profile.

It was being exalted as the latest unicorn and its founder, one of the youngest female tech billionaires.

We reviewed materials in the public domain as well as the pitch deck the investor had been given.

Our process highlighted some red flags, including:

  • Claims in the deck that lacked scientific evidence
  • Lack of peer reviews in recognised and reputable medical journals
  • The founder’s inability to answer questions with depth and substance
  • Deflection of questions
  • A board of the who’s who but no-one with relevant medical expertise

We shared our view with the investor.

He decided not to invest.

The company was Theranos, pre-scandal.

The investor is happy.

REAL IMPACT OR GREENWASHING?

REAL IMPACT OR GREENWASHING?

Recent years have seen an increase in ‘sustainability’ initiatives, but there is a difference between real impact and greenwashing. That difference lies in what gets measured and what gets done. Here are some questions to ascertain true impact.

read more
A FOUNDER TO BACK?

A FOUNDER TO BACK?

Most investors say they do due diligence on the team. We have found many fall short in picking up the telltale signs of potential risk factors and what needs to be done to increase the likelihood of success.

read more
WHEN INVESTORS COME IN

WHEN INVESTORS COME IN

Bringing investors on board can help a company scale, but difficulties can arise from growing too quickly. Here’s how we helped a high-growth company tackle transition and the associated growing pains.

read more
VISION + EXECUTION = VALUE

VISION + EXECUTION = VALUE

A budding entrepreneur wanted to create an investment company focused on Africa. We helped him define and shape the vision, as well as the values and behaviours he wanted to stand for and demonstrate. Wanting to ensure he could translate his vision into practice, we...

read more
HARMONISING CO-FOUNDERS

HARMONISING CO-FOUNDERS

A new venture had three founding partners all sharing the same vision. However, in trying to deliver on that vision, it became rapidly apparent they had different views on how that vision should be executed. We had to figure out if and how they could best work as a...

read more
SPOTTING ROGUES

SPOTTING ROGUES

Due diligence on people is an art and a science. The telltale signs lie in the subtleties, subtleties we translated into a red flag system. Here’s an example of how easy it is for rogues to slip through the net and the power of following the subtleties.

read more